Pfizer is by far the larger and better-established drugmaker. With a market cap of $156 billion, the pharmaceutical leader boasts a deep product portfolio across several therapeutic areas. Even with a ...

Six years after early vaccine trials, the legacy of COVID-19 shots reflects science, public debate, and how perceptions ...

A man used ChatGPT to cure his dog. Here are the stocks for the new age of programmable medicine. Pet owner Paul Conyngham (second right) and Professor Pall Thordarson discussed the cancer vaccine ...

Sometimes I’m happy to be wrong.

The ruling dealt a significant setback for the reduced childhood vaccination schedule championed by Kennedy, a longtime anti-vaccine activist.

By Nate Raymond, Ahmed Aboulenein and Leah Douglas BOSTON, March 16 (Reuters) - A federal judge on Monday blocked key parts ...

Monday blocked key parts of Health Secretary Robert F. vaccine policy, including a move to reduce the number of shots routinely recommended for children.

Pfizer (PFE) looks undervalued at 8–9x forward earnings with a ~7% yield; see how Seagen, cost cuts and the pipeline could drive $36–42 upside—read now.

Dozens of biotechs reported earnings this week. BioSpace recaps key highlights from Capricor Therapeutics, Legend Biotech, ...

A group of experts that advises the US Centers for Disease Control and Prevention on its vaccine recommendations has suspended an anticipated push to stop recommending mRNA-based Covid-19 vaccines ...

Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post. A key federal vaccine advisory panel has abandoned an attack on the covid-19 mRNA ...